These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33766260)

  • 1. Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery Disease.
    Andersson DP; Landucci L; Lagerros YT; Grotta A; Bellocco R; Lehtihet M; Holzmann MJ
    J Am Coll Cardiol; 2021 Mar; 77(12):1535-1550. PubMed ID: 33766260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Death in Patients With Coronary Artery Disease Taking Nitrates and Phosphodiesterase-5 Inhibitors.
    Trolle Lagerros Y; Grotta A; Freyland S; Grannas D; Andersson DP
    J Am Coll Cardiol; 2024 Jan; 83(3):417-426. PubMed ID: 38233015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction.
    Andersson DP; Trolle Lagerros Y; Grotta A; Bellocco R; Lehtihet M; Holzmann MJ
    Heart; 2017 Aug; 103(16):1264-1270. PubMed ID: 28280146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDE-5 inhibitors in monotherapy versus combination therapy in a sample of 1200 patients with erectile dysfunction.
    Labairu-Huerta L; Padilla-Fernández B; Arrondo-Arrondo JL; Valverde-Martínez LS; Martín-Rodríguez A; Silva-Abuín JM; García-Cenador MB; Mirón-Canelo JA; Lorenzo-Gómez MF
    Arch Ital Urol Androl; 2015 Sep; 87(3):204-9. PubMed ID: 26428641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality.
    Anderson SG; Hutchings DC; Woodward M; Rahimi K; Rutter MK; Kirby M; Hackett G; Trafford AW; Heald AH
    Heart; 2016 Nov; 102(21):1750-1756. PubMed ID: 27465053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
    Shkolyar E; Li S; Tang J; Eisenberg ML
    J Sex Med; 2018 Jul; 15(7):982-989. PubMed ID: 29884444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of phosphodiesterase type 5 inhibitors on major adverse cardiovascular events and overall mortality in a large nationwide cohort of men with erectile dysfunction and cardiovascular risk factors: A retrospective, observational study based on healthcare claims and national death index data.
    Kloner RA; Stanek E; Crowe CL; Singhal M; Pepe RS; Bradsher J; Rosen RC
    J Sex Med; 2023 Jan; 20(1):38-48. PubMed ID: 36897243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil with Survival in Men with Coronary Artery Disease.
    Reddy R; Diaz P; Ramasamy R
    Eur Urol; 2022 Jan; 81(1):120-121. PubMed ID: 34772548
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular Outcome Risks in Patients With Erectile Dysfunction Co-Prescribed a Phosphodiesterase Type 5 Inhibitor (PDE5i) and a Nitrate: A Retrospective Observational Study Using Electronic Health Record Data in the United States.
    Nunes AP; Seeger JD; Stewart A; Gupta A; McGraw T
    J Sex Med; 2021 Sep; 18(9):1511-1523. PubMed ID: 34389264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease: A Cohort Study.
    Adesuyan M; Jani YH; Alsugeir D; Howard R; Ju C; Wei L; Brauer R
    Neurology; 2024 Feb; 102(4):e209131. PubMed ID: 38324745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of intraurethral alprostadil in patients with erectile dysfunction refractory to treatment using phosphodiesterase-5 inhibitors.
    Garrido Abad P; Sinués Ojas B; Martínez Blázquez L; Conde Caturla P; Fernández Arjona M
    Actas Urol Esp; 2015 Dec; 39(10):635-40. PubMed ID: 26049734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails.
    Munk NE; Knudsen JS; Comerma-Steffensen S; Simonsen U
    Sex Med Rev; 2019 Jul; 7(3):430-441. PubMed ID: 30711478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sexual Rehabilitation After Nerve-Sparing Radical Prostatectomy: Free-of-Charge Phosphodiesterase Type 5 Inhibitor Administration Improves Compliance to Treatment.
    Siena G; Mari A; Canale A; Mondaini N; Chindemi A; Greco I; Saleh O; Serni S; Nicita G; Minervini A; Carini M
    J Sex Med; 2018 Feb; 15(2):120-123. PubMed ID: 29425663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Evaluation of a Clinical Care Pathway for the Management of Men With Nonorganic Erectile Dysfunction.
    Jenkins LC; Hall M; Deveci S; Guhring P; Parker M; Nelson CJ; Mulhall JP
    J Sex Med; 2019 Oct; 16(10):1541-1546. PubMed ID: 31444103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
    Loeb S; Folkvaljon Y; Robinson D; Schlomm T; Garmo H; Stattin P
    Eur Urol; 2016 Nov; 70(5):824-828. PubMed ID: 26743040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erectile Dysfunction Medications and Skin Cancer: An Analysis in US Veterans.
    Christie A; Vera PL; Higgins M; Kumar S; Lane M; Preston D
    Urology; 2019 Apr; 126():116-120. PubMed ID: 30735744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors.
    Campbell UB; Walker AM; Gaffney M; Petronis KR; Creanga D; Quinn S; Klein BE; Laties AM; Lewis M; Sharlip ID; Kolitsopoulos F; Klee BJ; Mo J; Reynolds RF
    J Sex Med; 2015 Jan; 12(1):139-51. PubMed ID: 25358826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.
    Lee M; Sharifi R
    Drugs Aging; 2018 Mar; 35(3):175-187. PubMed ID: 29464656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials.
    Giannetta E; Feola T; Gianfrilli D; Pofi R; Dall'Armi V; Badagliacca R; Barbagallo F; Lenzi A; Isidori AM
    BMC Med; 2014 Oct; 12():185. PubMed ID: 25330139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors.
    Schnetzler G; Banks I; Kirby M; Zou KH; Symonds T
    J Sex Med; 2010 Mar; 7(3):1237-46. PubMed ID: 20136707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.